Rev Esp Salud Publica. 2004 Mar-Apr;78(2):167-76.
[The European prospective investigation about cancer and nutrition (EPIC)]
[Article in Spanish]
González CA, Navarro C, Martínez C, Quirós JR, Dorronsoro M, Barricarte A, Tormo MJ, Agudo A, Chirlaque MD, Amiano P, Ardanaz E, Pera G, Sánchez MJ, Berenguer A.
Servicio de Epidemiología y Registro del Cáncer Institut Català d'Oncologia (ICO) Av. Gran Vía s/n, km 2,7, 08907 L'Hospitalet, Barcelona. cagonzalez@ico.scs.es
Abstract
EPIC is a prospective multi-center study coordinated by the International Agency for Research on Cancer (IARC) operating under the WHO which commenced in 1993 with the collecting of data and blood samples at twenty-three centers in ten European countries (Germany, Denmark, Spain, France, Greece, the Netherlands, Italy, Norway, the United Kingdom and Sweden). In Spain, this study was conducted in five geographic areas (Asturias, Granada, Guipuzcoa, Murcia and Navarre). This study included a total of 519,978 individuals (366,521 of whom were females), blood samples for laboratory analysis being available for a total of 385,719 of these individuals. To date, a total of 24,195 incident cancer cases have been identified. The results of the food intake comparison among the twenty-three European centers were published in 2002, in a European Nutrition journal supplement. The initial EPIC results concerning the relationship between diet and cancer show the intake of fiber, fruits and vegetables to have an effect on protect against colon and rectal cancer, the intake of fruits to have an effect on protect against lung cancer and the intake of fruits and vegetables on the upper digestive tract, whilst a high intake of fruits and vegetables has been shown to have no effect on prostate cancer. Using a seven-day diary for evaluating saturated fat intake, a high intake of saturated fats has been shown to increase the risk of breast cancer.
PMID: 15199795 [PubMed - indexed for MEDLINE]
miércoles, 22 de septiembre de 2010
miércoles, 4 de agosto de 2010
NEUTROFILOS Y TRATAMIENTO DEL CANCER
Tumour Cell Lines HT-29 and FaDu Produce Proinflammatory Cytokines and Activate Neutrophils In Vitro: Possible Applications for Neutrophil-Based Antitumour Treatment
AUTORES/AS: Antonio Brú,1 Juan-Carlos Souto,2 Sonia Alcolea,3 Rosa Antón,3 Angel Remacha,4 Mercedes Camacho,3 Marta Soler,3 Isabel Brú,5 Amelia Porres,6 and Luis Vila3:
1Applied Mathematics Department, Universidad Complutense de Madrid, 28040 Madrid, Spain
2Haematology Department, Institute of Research of Hospital Santa Creu i Sant Pau, 08025 Barcelona, Spain
3Laboratory of Angiology, Vascular Biology and Inflammation, Institute of Research of Hospital Santa Creu i Sant Pau, 08025 Barcelona, Spain
4Haematology Department, Complejo Hospitalario Virgen de la Salud, 45004 Toledo, Spain
5Centro de Salud La Estación, Talavera de la Reina, 45600 Toledo, Spain
6Research Laboratory, Fundación Jiménez Díaz, 28040 Madrid, Spain
Received 1 July 2009; Accepted 1 November 2009
Academic Editor: Eeva Moilanen
Mediators of InflammationVolume 2009 (2009), Article ID 817498, 13 pagesdoi:10.1155/2009/817498
AUTORES/AS: Antonio Brú,1 Juan-Carlos Souto,2 Sonia Alcolea,3 Rosa Antón,3 Angel Remacha,4 Mercedes Camacho,3 Marta Soler,3 Isabel Brú,5 Amelia Porres,6 and Luis Vila3:
1Applied Mathematics Department, Universidad Complutense de Madrid, 28040 Madrid, Spain
2Haematology Department, Institute of Research of Hospital Santa Creu i Sant Pau, 08025 Barcelona, Spain
3Laboratory of Angiology, Vascular Biology and Inflammation, Institute of Research of Hospital Santa Creu i Sant Pau, 08025 Barcelona, Spain
4Haematology Department, Complejo Hospitalario Virgen de la Salud, 45004 Toledo, Spain
5Centro de Salud La Estación, Talavera de la Reina, 45600 Toledo, Spain
6Research Laboratory, Fundación Jiménez Díaz, 28040 Madrid, Spain
Received 1 July 2009; Accepted 1 November 2009
Academic Editor: Eeva Moilanen
Mediators of InflammationVolume 2009 (2009), Article ID 817498, 13 pagesdoi:10.1155/2009/817498
jueves, 22 de julio de 2010
MD ANDERSON CENTER-The Power of Sustainable Changes in Diet and Lifestyle
Link con un video de 1 hora en el que se presenta y aborda el sistema de dieta, complementos alimenticios, y cambios de vida no ya como prevención, como en muchos artículos de divulgación general, sino como tratamiento del cancer.
En el video intervienen varios especialistas, y en la página web de la clínica Anderson, apartado "multimedia educational tools", está dividido en varios videos,uno para cada especialista.
VER: http://www3.mdanderson.org/streams/FullVideoPlayer.cfm?xml=publicEd%2Fconfig%2FDiet-Exercise-Ornish--cfg
INFORMACION COMPLEMENTARIA en la web de la Clínica Anderson, poniendo en su buscador: INTEGRATIVE.
En el video intervienen varios especialistas, y en la página web de la clínica Anderson, apartado "multimedia educational tools", está dividido en varios videos,uno para cada especialista.
VER: http://www3.mdanderson.org/streams/FullVideoPlayer.cfm?xml=publicEd%2Fconfig%2FDiet-Exercise-Ornish--cfg
INFORMACION COMPLEMENTARIA en la web de la Clínica Anderson, poniendo en su buscador: INTEGRATIVE.
jueves, 15 de julio de 2010
What is the point: will screening mammography save my life?-¿ Hacerme una mamografía, puede salvar mi vida..?
REVISTA: BMC Med Inform Decis Mak. 2009 Apr 2;9:18.
AUTOR: Keen JD, Keen JE.
DONDE: Department of Radiology, John H Stroger Jr Hospital of Cook County, 1901 West Harrison Street, Chicago, IL 60612-9985, USA. jkeen@ccbhs.org. USA.
Comment in:
BMC Med Inform Decis Mak. 2009;9:19.
BMC Med Inform Decis Mak. 2009;9:20.
Abstract/RESUMEN
BACKGROUND: We analyzed the claim "mammography saves lives" by calculating the life-saving absolute benefit of screening mammography in reducing breast cancer mortality in women ages 40 to 65.
METHODS: To calculate the absolute benefit, we first estimated the screen-free absolute death risk from breast cancer by adjusting the Surveillance, Epidemiology and End Results Program 15-year cumulative breast cancer mortality to account for the separate effects of screening mammography and improved therapy. We calculated the absolute risk reduction (reduction in absolute death risk), the number needed to screen assuming repeated screening, and the survival percentages without and with screening. We varied the relative risk reduction from 10%-30% based on the randomized trials of screening mammography. We developed additional variations of the absolute risk reduction for a screening intervention, including the average benefit of a single screen, as well as the life-saving proportion among patients with earlier cancer detection.
RESULTS: Because the screen-free absolute death risk is approximately 1% overall but rises with age, the relative risk reduction from repeated screening mammography is about 100 times the absolute risk reduction between the starting ages of 50 and 60. Assuming a base case 20% relative risk reduction, repeated screening starting at age 50 saves about 1.8 (overall range, 0.9-2.7) lives over 15 years for every 1000 women screened. The number needed to screen repeatedly is 1000/1.8, or 570. The survival percentage is 99.12% without and 99.29% with screening.
The average benefit of a single screening mammogram is 0.034%, or 2970 women must be screened once to save one life. Mammography saves 4.3% of screen-detectable cancer patients' lives starting at age 50. This means 23 cancers must be found starting at age 50, or 27 cancers at age 40 and 21 cancers at age 65, to save one life.
CONCLUSION: The life-saving absolute benefit of screening mammography increases with age as the absolute death risk increases. The number of events needed to save one life varies depending on the prospective screening subset or reference class. Less than 5% of women with screen-detectable cancers have their lives saved.
AUTOR: Keen JD, Keen JE.
DONDE: Department of Radiology, John H Stroger Jr Hospital of Cook County, 1901 West Harrison Street, Chicago, IL 60612-9985, USA. jkeen@ccbhs.org. USA.
Comment in:
BMC Med Inform Decis Mak. 2009;9:19.
BMC Med Inform Decis Mak. 2009;9:20.
Abstract/RESUMEN
BACKGROUND: We analyzed the claim "mammography saves lives" by calculating the life-saving absolute benefit of screening mammography in reducing breast cancer mortality in women ages 40 to 65.
METHODS: To calculate the absolute benefit, we first estimated the screen-free absolute death risk from breast cancer by adjusting the Surveillance, Epidemiology and End Results Program 15-year cumulative breast cancer mortality to account for the separate effects of screening mammography and improved therapy. We calculated the absolute risk reduction (reduction in absolute death risk), the number needed to screen assuming repeated screening, and the survival percentages without and with screening. We varied the relative risk reduction from 10%-30% based on the randomized trials of screening mammography. We developed additional variations of the absolute risk reduction for a screening intervention, including the average benefit of a single screen, as well as the life-saving proportion among patients with earlier cancer detection.
RESULTS: Because the screen-free absolute death risk is approximately 1% overall but rises with age, the relative risk reduction from repeated screening mammography is about 100 times the absolute risk reduction between the starting ages of 50 and 60. Assuming a base case 20% relative risk reduction, repeated screening starting at age 50 saves about 1.8 (overall range, 0.9-2.7) lives over 15 years for every 1000 women screened. The number needed to screen repeatedly is 1000/1.8, or 570. The survival percentage is 99.12% without and 99.29% with screening.
The average benefit of a single screening mammogram is 0.034%, or 2970 women must be screened once to save one life. Mammography saves 4.3% of screen-detectable cancer patients' lives starting at age 50. This means 23 cancers must be found starting at age 50, or 27 cancers at age 40 and 21 cancers at age 65, to save one life.
CONCLUSION: The life-saving absolute benefit of screening mammography increases with age as the absolute death risk increases. The number of events needed to save one life varies depending on the prospective screening subset or reference class. Less than 5% of women with screen-detectable cancers have their lives saved.
martes, 29 de junio de 2010
The Universal Dynamics of Tumor Growth-Las dinámicas universales de los crecimientos tumorales
Biophysical Journal Volume 85 November 2003 2948–2961
Antonio Bru, Sonia Albertos,y Jose Luis Subiza,Jose Lopez García-Asenjo and Isabel Bru
ARTICULO COMPLETO EN: http://www.pathology.med.ohio-state.edu/ext/MedEd/Course640/The%20Universal%20Dynamics%20(Vandre).pdf
*CCMA, Consejo Superior de Investigaciones Cientıficas, 28006 Madrid, Spain; y Servicio de Aparato Digestivo,Hospital Clınico San Carlos, 28003 Madrid, Spain; Servicio de Inmunología, Hospital Clínico San Carlos, 28003 Madrid, Spain;
Servicio de Anatomía Patologica, Hospital Clínico San Carlos, 28003 Madrid, Spain; and Centro de Salud La Estacion,45600 Talavera de La Reina, Toledo, Spain.
ABSTRACT
Scaling techniques were used to analyze the fractal nature of colonies of 15 cell lines growing in vitro as well as of 16 types of tumor developing in vivo. All cell colonies were found to exhibit exactly the same growth dynamics—which correspond to the molecular beam epitaxy (MBE) universality class. MBE dynamics are characterized by 1), a linear growth rate, 2), the constraint of cell proliferation to the colony/tumor border, and 3), surface diffusion of cells at the growing edge.
These characteristics were experimentally verified in the studied colonies. That these should show MBE dynamics is in strong contrast with the currently established concept of tumor growth: the kinetics of this type of proliferation rules out exponential or Gompertzian growth. Rather, a clear linear growth regime is followed.
The importance of new cell movements—cell diffusion at the tumor border—lies in the fact that tumor growth must be conceived as a competition for space between the tumor and the host, and not for nutrients or other factors. Strong experimental evidence is presented for 16 types of tumor, the growth of which cell surface diffusion may be the main mechanism responsible in vivo. These results explain most of the clinical and biological features of colonies and tumors, offer new theoretical frameworks, and challenge the wisdom of some current clinical strategies.
MAS INFORMACION SOBRE EL TRABAJO DE ANTONIO BRU Y SUS ARTICULOS CIENTIFICOS RECIENTES EN: EN "GOOGLE ACADEMICO"
Antonio Bru, Sonia Albertos,y Jose Luis Subiza,Jose Lopez García-Asenjo and Isabel Bru
ARTICULO COMPLETO EN: http://www.pathology.med.ohio-state.edu/ext/MedEd/Course640/The%20Universal%20Dynamics%20(Vandre).pdf
*CCMA, Consejo Superior de Investigaciones Cientıficas, 28006 Madrid, Spain; y Servicio de Aparato Digestivo,Hospital Clınico San Carlos, 28003 Madrid, Spain; Servicio de Inmunología, Hospital Clínico San Carlos, 28003 Madrid, Spain;
Servicio de Anatomía Patologica, Hospital Clínico San Carlos, 28003 Madrid, Spain; and Centro de Salud La Estacion,45600 Talavera de La Reina, Toledo, Spain.
ABSTRACT
Scaling techniques were used to analyze the fractal nature of colonies of 15 cell lines growing in vitro as well as of 16 types of tumor developing in vivo. All cell colonies were found to exhibit exactly the same growth dynamics—which correspond to the molecular beam epitaxy (MBE) universality class. MBE dynamics are characterized by 1), a linear growth rate, 2), the constraint of cell proliferation to the colony/tumor border, and 3), surface diffusion of cells at the growing edge.
These characteristics were experimentally verified in the studied colonies. That these should show MBE dynamics is in strong contrast with the currently established concept of tumor growth: the kinetics of this type of proliferation rules out exponential or Gompertzian growth. Rather, a clear linear growth regime is followed.
The importance of new cell movements—cell diffusion at the tumor border—lies in the fact that tumor growth must be conceived as a competition for space between the tumor and the host, and not for nutrients or other factors. Strong experimental evidence is presented for 16 types of tumor, the growth of which cell surface diffusion may be the main mechanism responsible in vivo. These results explain most of the clinical and biological features of colonies and tumors, offer new theoretical frameworks, and challenge the wisdom of some current clinical strategies.
MAS INFORMACION SOBRE EL TRABAJO DE ANTONIO BRU Y SUS ARTICULOS CIENTIFICOS RECIENTES EN: EN "GOOGLE ACADEMICO"
viernes, 11 de junio de 2010
HUFELAND KLINIK-CASOS PRACTICOS-Editorial SAGE
Integrative Cancer Therapies 2005; 4; 156
I. Neugut Judith S. Jacobson, Victor R. Grann, Michael A. Gnatt, Hanina Hibshoosh, John H.M. Austin, William S. Millar and Alfred
Review
Cancer Outcomes at the Hufeland (Complementary/Alternative Medicine) Klinik: A Best-Case Series
http://ict.sagepub.com/cgi/content/abstract/4/2/156
The online version of this article can be found at:
Published by:
http://www.sagepublications.com
Additional
HUFELAND KLINIK: http://www.hufeland-klinik.de/
Tratamiento ambulatorio para pacientes extranjeros/as.
I. Neugut Judith S. Jacobson, Victor R. Grann, Michael A. Gnatt, Hanina Hibshoosh, John H.M. Austin, William S. Millar and Alfred
Review
Cancer Outcomes at the Hufeland (Complementary/Alternative Medicine) Klinik: A Best-Case Series
http://ict.sagepub.com/cgi/content/abstract/4/2/156
The online version of this article can be found at:
Published by:
http://www.sagepublications.com
Additional
HUFELAND KLINIK: http://www.hufeland-klinik.de/
Tratamiento ambulatorio para pacientes extranjeros/as.
viernes, 28 de mayo de 2010
EFFECTS OF FR 91 ON HUMAN TUMOR CELL LINES
EUROESPES JOURNAL
http://www.gen-t.es/edicion_virtual/revista_gen-t4.html
ARTICULO EN INGLÉS SOBRE LOS PRINCIPIOS ACTIVOS DE NUEVAS TERAPIAS ONCOLOGICAS.
pag 50
También: http://www.ncbi.nlm.nih.gov/pubmed/19606255
Effects of FR-91 on immune cells from healthy individuals and from patients with non-Hodgkin lymphoma.Lombardi VR, Martínez E, Chacón R, Etcheverría I, Cacabelos R.Departamento de Inmunología Celular, Euroespes Biotecnologia, La Coruña, 15166 Bergondo, Spain. biotecnologia@ebiotec.com
http://www.gen-t.es/edicion_virtual/revista_gen-t4.html
ARTICULO EN INGLÉS SOBRE LOS PRINCIPIOS ACTIVOS DE NUEVAS TERAPIAS ONCOLOGICAS.
pag 50
También: http://www.ncbi.nlm.nih.gov/pubmed/19606255
Effects of FR-91 on immune cells from healthy individuals and from patients with non-Hodgkin lymphoma.Lombardi VR, Martínez E, Chacón R, Etcheverría I, Cacabelos R.Departamento de Inmunología Celular, Euroespes Biotecnologia, La Coruña, 15166 Bergondo, Spain. biotecnologia@ebiotec.com
Suscribirse a:
Entradas (Atom)
